Jazz Pharmaceuticals (JAZZ) to Release Quarterly Earnings on Tuesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) is expected to be releasing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Jazz Pharmaceuticals to post earnings of $6.49 per share and revenue of $1.1660 billion for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $166.31 on Tuesday. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The stock’s 50-day moving average is $167.54 and its two-hundred day moving average is $147.79. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The firm has a market cap of $10.10 billion, a P/E ratio of -27.40, a price-to-earnings-growth ratio of 0.89 and a beta of 0.26.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $177.78, for a total transaction of $607,118.70. Following the transaction, the director owned 20,449 shares in the company, valued at approximately $3,635,423.22. The trade was a 14.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bruce C. Cozadd sold 77,500 shares of the stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the completion of the sale, the director owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. The trade was a 16.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 87,813 shares of company stock worth $15,564,549. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $127,344,000. Schonfeld Strategic Advisors LLC lifted its position in Jazz Pharmaceuticals by 592.1% in the third quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock worth $57,523,000 after purchasing an additional 373,383 shares during the period. AQR Capital Management LLC boosted its stake in Jazz Pharmaceuticals by 62.1% during the second quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock worth $84,341,000 after buying an additional 304,463 shares in the last quarter. Woodline Partners LP increased its holdings in Jazz Pharmaceuticals by 710.7% in the 3rd quarter. Woodline Partners LP now owns 264,968 shares of the specialty pharmaceutical company’s stock valued at $34,923,000 after buying an additional 232,284 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after buying an additional 209,667 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on JAZZ shares. Needham & Company LLC raised their price objective on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Royal Bank Of Canada set a $194.00 target price on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday, November 17th. Fourteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $205.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.